Online inquiry

IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6103MR)

This product GTTS-WQ6103MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6103MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3571MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ5181MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ15749MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ15211MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ10482MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ15607MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ9878MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ13385MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1594804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW